• Moonlake Immunotherapeutics held its annual meeting on June 4, 2026.
• Shareholders adopted an amended and restated 2022 Equity Incentive Plan, increasing the share pool by 5 million.
• The plan changes also remove liberal share recycling, add a one-year minimum vesting requirement, set change-in-control treatment, revise director limits, extend the term to June 4, 2036.
• Shareholders ratified Baker Tilly US, LLP as independent auditor.
• Shareholders backed a non-binding advisory resolution on executive compensation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-066821), on June 09, 2026, and is solely responsible for the information contained therein.